An Open-Label Phase 1 Study to Evaluate the Safety of ATA188 in Subjects with Progressive and Relapsing-Remitting Multiple Sclerosis

An Open-Label Phase 1 Study to Evaluate the Safety of ATA188 in Subjects with Progressive and Relapsing-Remitting Multiple Sclerosis

Brief description of study

The purpose of the study is to determine the safety and tolerability of ATA188 in subjects with progressive forms of multiple sclerosis. Up to 42 male or female subjects with progressive forms of MS and 42 subjects with Relapsing-Remitting MS will be enrolled. The subjects will be randomized to receive study drug or placebo and will receive 2 treatment cycles followed by 11 monthly follow-up visits.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    TBD
  • Age: - 99 Years
  • Gender: All


Updated on 11 Aug 2022. Study ID: 830135

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center